May 22, 2024 03:12 PM EDT
Deals
Cell/Gene Tx
Manufacturing

Mer­ck KGaA makes $600M bet to boost man­u­fac­tur­ing for vi­ral vec­tors

Max Gelman

Senior Editor

Mer­ck KGaA an­nounced Wednes­day that it is ac­quir­ing Mirus Bio, a start­up that de­vel­ops trans­fec­tion reagents for vi­ral cell and gene ther­a­pies, for $600 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times